Mesirow Institutional Investment Management Inc. Grows Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Mesirow Institutional Investment Management Inc. increased its position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 24.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 153,797 shares of the medical equipment provider's stock after acquiring an additional 29,774 shares during the quarter. Mesirow Institutional Investment Management Inc. owned about 0.22% of Lantheus worth $13,759,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. MML Investors Services LLC raised its stake in Lantheus by 24.6% during the 3rd quarter. MML Investors Services LLC now owns 4,338 shares of the medical equipment provider's stock valued at $476,000 after purchasing an additional 857 shares during the period. World Investment Advisors LLC bought a new stake in shares of Lantheus during the third quarter valued at approximately $60,000. Wilmington Savings Fund Society FSB purchased a new position in shares of Lantheus in the third quarter worth $25,000. Tidal Investments LLC boosted its position in shares of Lantheus by 25.2% during the third quarter. Tidal Investments LLC now owns 17,621 shares of the medical equipment provider's stock worth $1,934,000 after acquiring an additional 3,547 shares during the last quarter. Finally, GAMMA Investing LLC grew its stake in Lantheus by 118.0% during the fourth quarter. GAMMA Investing LLC now owns 1,018 shares of the medical equipment provider's stock valued at $91,000 after acquiring an additional 551 shares in the last quarter. Institutional investors own 99.06% of the company's stock.

Analyst Ratings Changes

Several analysts have commented on the stock. Truist Financial boosted their price target on shares of Lantheus from $120.00 to $127.00 and gave the stock a "buy" rating in a research note on Thursday, February 27th. JMP Securities reissued a "market outperform" rating and set a $112.00 price target on shares of Lantheus in a research note on Tuesday, January 14th. Finally, B. Riley reduced their price objective on Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a research note on Friday, March 21st. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $129.43.

Insider Activity at Lantheus

In other news, Director Mary Anne Heino sold 53,107 shares of the business's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the transaction, the director now directly owns 440,399 shares of the company's stock, valued at approximately $41,551,645.65. The trade was a 10.76 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the firm's stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $100.52, for a total value of $1,005,200.00. Following the sale, the chief financial officer now directly owns 113,860 shares in the company, valued at approximately $11,445,207.20. The trade was a 8.07 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 63,109 shares of company stock worth $6,016,046 in the last 90 days. 2.00% of the stock is owned by corporate insiders.

Lantheus Price Performance

Shares of NASDAQ:LNTH traded up $1.63 during trading on Wednesday, hitting $101.20. The company had a trading volume of 580,149 shares, compared to its average volume of 953,816. The stock has a market cap of $6.93 billion, a price-to-earnings ratio of 16.84 and a beta of 0.20. The company has a fifty day simple moving average of $96.54 and a two-hundred day simple moving average of $95.40. Lantheus Holdings, Inc. has a one year low of $63.61 and a one year high of $126.89.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing analysts' consensus estimates of $1.57 by ($0.23). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The firm had revenue of $391.11 million for the quarter, compared to analysts' expectations of $376.61 million. On average, equities research analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.